Skye Bioscience Completes Enrollment of Phase 2a Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension
All treated patients completed the study, with no early discontinuations due to adverse events.
- All treated patients completed the study, with no early discontinuations due to adverse events.
- “Because this trial completed enrollment ahead of schedule, our initially intended interim data report based on partial enrollment is unnecessary.
- Skye is evaluating SBI-100 OE’s ability to lower IOP, safety and relevant biomarkers in patients with POAG or OHT.
- Low rate of hyperaemia (red eyes) of 8.4% compared to higher rates in other leading classes of glaucoma drugs.